Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.25 -2.7 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,065.00 GF Score: 78/100

Alnylam Pharmaceuticals Inc to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress Conference Call Transcript

Apr 13, 2019 / 12:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss results from ENVISION Phase III study on givosiran.

(Operator Instructions) Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - VP of IR & Communications

Good morning. I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam.

With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Barry Greene, our President. Also joining us in the room and available for Q&A is Akin Akinc, general manager of the givosiran program.

For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the investor page of our website, www.alnylam.com.

Now turning

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot